{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:13:06Z","timestamp":1792253586259,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jfma.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T20:11:13Z","timestamp":1429215073000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis"],"prefix":"10.1016","volume":"115","author":[{"given":"I-Chun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-5306","authenticated-orcid":false,"given":"I-Shiow","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2015.03.005_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02967-X","article-title":"Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study","volume":"54","author":"Mahmoud-Ahmed","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jfma.2015.03.005_bib2","doi-asserted-by":"crossref","first-page":"819210","DOI":"10.1155\/2012\/819210","article-title":"Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer","volume":"2012","author":"Danese","year":"2012","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.jfma.2015.03.005_bib3","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1002\/cncr.26716","article-title":"Predicting survival in women with breast cancer and brain metastasis: a nomogram outperforms current survival prediction models","volume":"118","author":"Marko","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2015.03.005_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2010.30.2174","article-title":"How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials","volume":"29","author":"Kiely","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib5","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/oxfordjournals.annonc.a010755","article-title":"Carinomatous meningitis in solid tumours","volume":"7","author":"Jayson","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","article-title":"The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group","volume":"6","author":"Borgelt","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jfma.2015.03.005_bib9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2015.03.005_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jnci\/87.1.34","article-title":"Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases","volume":"87","author":"Alexander","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2015.03.005_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-012-1893-z","article-title":"IntraCSF administration of chemotherapy medications","volume":"70","author":"Gabay","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jfma.2015.03.005_bib13","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The blood\u2013brain barrier and cancer: transporters, treatment, and Trojan horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2015.03.005_bib14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","article-title":"Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study","volume":"85","author":"Franciosi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2015.03.005_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CBC.2009.n.021","article-title":"Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series","volume":"9","author":"Labidi","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jfma.2015.03.005_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.breast.2012.10.009","article-title":"Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis","volume":"22","author":"Torrejon","year":"2013","journal-title":"Breast"},{"issue":"Suppl. 4","key":"10.1016\/j.jfma.2015.03.005_bib17","doi-asserted-by":"crossref","first-page":"iv285","DOI":"10.1093\/annonc\/mdh941","article-title":"The diagnostic and therapeutic management of leptomeningeal carcinomatosis","volume":"15","author":"Pavlidis","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/00023210-200721070-00003","article-title":"CNS complications of breast cancer: current and emerging treatment options","volume":"21","author":"Kaal","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jfma.2015.03.005_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ana.410170121","article-title":"Leptomeningeal metastases: reduction in cerebral blood flow and cognitive impairment","volume":"17","author":"Siegal","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jfma.2015.03.005_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.breast.2011.05.007","article-title":"Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis","volume":"20","author":"Mego","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.jfma.2015.03.005_bib21","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.54.8.1670","article-title":"Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis","volume":"54","author":"Stockhammer","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2015.03.005_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bjc.6601953","article-title":"Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value","volume":"91","author":"Herrlinger","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2015.03.005_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.surneu.2007.06.029","article-title":"The effect of bevacizumab (Avastin) on neuroimaging of brain metastases","volume":"70","author":"Mathews","year":"2008","journal-title":"Surg Neurol"},{"key":"10.1016\/j.jfma.2015.03.005_bib24","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2015.03.005_bib25","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jfma.2015.03.005_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.oraloncology.2011.04.001","article-title":"Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts","volume":"47","author":"Cao","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","article-title":"Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of antiangiogenic drugs","volume":"21","author":"Van der Veldt","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jfma.2015.03.005_bib28","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.1076","article-title":"Does chemotherapy schedule matter when combining with bevacizumab? A stratified meta-analysis of randomized controlled trials","volume":"32","author":"Chang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib29","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib30","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib31","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2015.03.005_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-011-1695-8","article-title":"Final overall survival results and effect of prolonged (\u2265 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial","volume":"130","author":"Smith","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jfma.2015.03.005_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/annonc\/mdr043","article-title":"First-line bevacizumab-containing therapy for breast cancer: results in patients aged \u226570 years treated in the ATHENA study","volume":"23","author":"Biganzoli","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib34","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2015.03.005_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16","author":"Besse","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2015.03.005_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s002800050391","article-title":"Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor","volume":"37","author":"Nakagawa","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jfma.2015.03.005_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF00686001","article-title":"Penetration of etoposide into human malignant brain tumors after intravenous and oral administration","volume":"29","author":"Kiya","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jfma.2015.03.005_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20072041","article-title":"VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma","volume":"205","author":"Maharaj","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jfma.2015.03.005_bib39","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-2075","article-title":"Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy","author":"Lu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2015.03.005_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.513","article-title":"Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM)","volume":"31","author":"Lin","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664615001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664615001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:07:12Z","timestamp":1598918832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664615001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0929664615001333"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2015.03.005","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier (Singapore) Pte Ltd.","name":"copyright","label":"Copyright"}]}}